SG11201704618RA - Hydroxy containing fxr (nr1h4) modulating compounds - Google Patents
Hydroxy containing fxr (nr1h4) modulating compoundsInfo
- Publication number
- SG11201704618RA SG11201704618RA SG11201704618RA SG11201704618RA SG11201704618RA SG 11201704618R A SG11201704618R A SG 11201704618RA SG 11201704618R A SG11201704618R A SG 11201704618RA SG 11201704618R A SG11201704618R A SG 11201704618RA SG 11201704618R A SG11201704618R A SG 11201704618RA
- Authority
- SG
- Singapore
- Prior art keywords
- nr1h4
- modulating compounds
- hydroxy containing
- fxr
- containing fxr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14004259.9A EP3034501A1 (en) | 2014-12-17 | 2014-12-17 | Hydroxy containing FXR (NR1H4) modulating compounds |
| PCT/EP2015/002511 WO2016096115A1 (en) | 2014-12-17 | 2015-12-14 | Hydroxy containing fxr (nr1h4) modulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704618RA true SG11201704618RA (en) | 2017-07-28 |
Family
ID=52338776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704618RA SG11201704618RA (en) | 2014-12-17 | 2015-12-14 | Hydroxy containing fxr (nr1h4) modulating compounds |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9751874B2 (en) |
| EP (2) | EP3034501A1 (en) |
| JP (1) | JP6452820B2 (en) |
| KR (1) | KR101998007B1 (en) |
| CN (1) | CN108064223B (en) |
| AU (1) | AU2015365944B2 (en) |
| BR (1) | BR102015031718A2 (en) |
| CA (1) | CA2971240C (en) |
| EA (1) | EA201791017A1 (en) |
| ES (1) | ES2730757T3 (en) |
| HK (1) | HK1251552A1 (en) |
| IL (1) | IL252677A0 (en) |
| MX (1) | MX2017007981A (en) |
| NZ (1) | NZ732246A (en) |
| PL (1) | PL3233850T3 (en) |
| PT (1) | PT3233850T (en) |
| SG (1) | SG11201704618RA (en) |
| SI (1) | SI3233850T1 (en) |
| TR (1) | TR201909093T4 (en) |
| TW (1) | TWI697483B (en) |
| UY (1) | UY36445A (en) |
| WO (1) | WO2016096115A1 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| TWI698430B (en) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | Tricyclic compounds and uses thereof in medicine |
| DK3277286T3 (en) | 2015-03-31 | 2021-07-05 | Enanta Pharm Inc | BILE SYDER DERIVATIVES AS FXR / TGR5 AGONISTS AND METHODS OF USE THEREOF |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| AR108711A1 (en) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | FXR MODULATING COMPOUNDS (NR1H4) |
| EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
| TW201808283A (en) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | Nitrogen-containing tricyclic compounds and uses thereof in medicine |
| WO2018059314A1 (en) * | 2016-09-28 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | Azabicycle derivatives and preparation method and use thereof |
| WO2018067704A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| EP3571205B1 (en) * | 2017-01-22 | 2023-08-30 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
| DK3612520T3 (en) | 2017-04-12 | 2021-12-06 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| MX2020000268A (en) * | 2017-07-06 | 2020-07-22 | Xuanzhu Biopharmaceutical Co Ltd | Fxr receptor agonist. |
| CN109320509B (en) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | FXR receptor agonists |
| JP7271513B2 (en) | 2017-09-14 | 2023-05-11 | アルデリックス， インコーポレイテッド | Hormone receptor modulators for treating metabolic-related mutagenic and fibrotic conditions and disorders |
| WO2019089664A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
| PE20201170A1 (en) * | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | BRIDGE BICYCLE COMPOUNDS AS MODULATORS OF THE X FARNESOID RECEIVER |
| WO2019089670A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| AU2018357878A1 (en) * | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid X receptor modulators |
| KR20200083529A (en) * | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| WO2019118571A1 (en) * | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
| CN110128432B (en) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | Nitrogenous tricyclic compound and application thereof in medicine |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN112638473B (en) | 2018-08-08 | 2022-06-07 | 因奥必治疗有限公司 | Compounds for modulating farnesoid X receptors and methods of making and using the same |
| EP4360632A2 (en) | 2019-01-15 | 2024-05-01 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| AR118050A1 (en) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | BICYCLIC COMPOUNDS REPLACED AS MODULATORS OF THE FARNESOID X RECEIVER |
| AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| EP3957640A4 (en) * | 2019-04-19 | 2022-12-14 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Fxr small molecule agonist and preparation method therefor and use thereof |
| CN111825667B (en) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | FXR small molecule agonist and preparation method and application thereof |
| WO2020231917A1 (en) * | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| KR20220035365A (en) | 2019-07-18 | 2022-03-22 | 엔요 파마 | How to reduce the side effects of interferon |
| KR20220038368A (en) | 2019-07-23 | 2022-03-28 | 노파르티스 아게 | Combination treatment of liver disease with FXR agonists |
| CA3142904A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| JOP20220057A1 (en) | 2019-09-03 | 2023-01-30 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| CN114401745A (en) | 2019-09-19 | 2022-04-26 | 诺华股份有限公司 | Treatment comprising FXR agonists |
| US20220331341A1 (en) | 2019-09-30 | 2022-10-20 | Novartis Ag | Treatment comprising the use of fxr agonists |
| CA3164941A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN114195786B (en) * | 2020-09-18 | 2023-08-22 | 凯思凯迪（上海）医药科技有限公司 | Preparation and application of novel FXR small molecule agonist |
| CN114195776B (en) * | 2020-09-18 | 2023-06-20 | 凯思凯迪（上海）医药科技有限公司 | Preparation and application of novel FXR small molecule agonist |
| CN114195777B (en) * | 2020-09-18 | 2023-06-20 | 凯思凯迪（上海）医药科技有限公司 | Preparation and application of novel FXR small molecule agonist |
| CN114315830A (en) * | 2020-09-30 | 2022-04-12 | 中国科学院上海药物研究所 | FXR small molecule agonist and preparation method and application thereof |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| TW202308629A (en) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN117865941A (en) * | 2024-03-13 | 2024-04-12 | 上海方予健康医药科技有限公司 | Substituted piperidine compounds, process for their preparation and their use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| ATE381542T1 (en) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | NR1H4 CORE RECEPTOR BINDING COMPOUNDS |
| WO2003080803A2 (en) | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| US20070166710A1 (en) | 2003-03-31 | 2007-07-19 | Markus Stoffel | Methods for inhibiting adipogenesis and for treating type 2 diabetes |
| ATE526318T1 (en) | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | FARNESOID-X RECEPTOR AGONISTS |
| JP5301286B2 (en) | 2006-02-03 | 2013-09-25 | イーライ リリー アンド カンパニー | Compounds and methods for modulating FX receptors |
| ATE460403T1 (en) | 2006-05-24 | 2010-03-15 | Lilly Co Eli | COMPOUNDS AND METHODS FOR MODULATING FX RECEPTORS |
| ATE465996T1 (en) | 2006-05-24 | 2010-05-15 | Lilly Co Eli | FXR AGONISTS |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| CL2007003035A1 (en) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | COMPOUNDS DERIVED FROM ISOXAZOL REPLACED, FARNESOID X RECEIVER AGONISTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND USE OF THE COMPOUND IN THE TREATMENT OF OBESITY, DIABETES MELLITUS, FIBROSIS IN ORGANS, |
| US20100249179A1 (en) | 2007-06-13 | 2010-09-30 | Smithkline Beecham Corporation | Farnesoid X Receptor Agonists |
| EP2173174A4 (en) | 2007-07-02 | 2010-08-04 | Glaxosmithkline Llc | Farnesoid x receptor agonists |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| AU2008339572B2 (en) * | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US20140039007A1 (en) | 2010-12-20 | 2014-02-06 | David C. Tully | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (en) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
| US20130261108A1 (en) | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
-
2014
- 2014-12-17 EP EP14004259.9A patent/EP3034501A1/en not_active Withdrawn
-
2015
- 2015-12-14 EA EA201791017A patent/EA201791017A1/en unknown
- 2015-12-14 PL PL15816665T patent/PL3233850T3/en unknown
- 2015-12-14 EP EP15816665.2A patent/EP3233850B1/en active Active
- 2015-12-14 TR TR2019/09093T patent/TR201909093T4/en unknown
- 2015-12-14 CN CN201580069167.6A patent/CN108064223B/en active Active
- 2015-12-14 AU AU2015365944A patent/AU2015365944B2/en active Active
- 2015-12-14 KR KR1020177019299A patent/KR101998007B1/en active IP Right Grant
- 2015-12-14 SG SG11201704618RA patent/SG11201704618RA/en unknown
- 2015-12-14 SI SI201530742T patent/SI3233850T1/en unknown
- 2015-12-14 JP JP2017530023A patent/JP6452820B2/en active Active
- 2015-12-14 CA CA2971240A patent/CA2971240C/en active Active
- 2015-12-14 ES ES15816665T patent/ES2730757T3/en active Active
- 2015-12-14 PT PT15816665T patent/PT3233850T/en unknown
- 2015-12-14 WO PCT/EP2015/002511 patent/WO2016096115A1/en active Application Filing
- 2015-12-14 NZ NZ732246A patent/NZ732246A/en unknown
- 2015-12-14 MX MX2017007981A patent/MX2017007981A/en active IP Right Grant
- 2015-12-16 UY UY0001036445A patent/UY36445A/en not_active Application Discontinuation
- 2015-12-16 US US14/971,875 patent/US9751874B2/en active Active
- 2015-12-17 TW TW104142586A patent/TWI697483B/en active
- 2015-12-17 BR BR102015031718A patent/BR102015031718A2/en not_active IP Right Cessation
-
2017
- 2017-06-05 IL IL252677A patent/IL252677A0/en unknown
-
2018
- 2018-08-23 HK HK18110840.1A patent/HK1251552A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3034501A1 (en) | 2016-06-22 |
| AU2015365944B2 (en) | 2019-01-17 |
| WO2016096115A1 (en) | 2016-06-23 |
| IL252677A0 (en) | 2017-08-31 |
| PT3233850T (en) | 2019-06-19 |
| US20160176861A1 (en) | 2016-06-23 |
| TR201909093T4 (en) | 2019-07-22 |
| JP6452820B2 (en) | 2019-01-16 |
| CA2971240C (en) | 2019-07-02 |
| TWI697483B (en) | 2020-07-01 |
| KR101998007B1 (en) | 2019-07-08 |
| HK1251552A1 (en) | 2019-02-01 |
| MX2017007981A (en) | 2017-09-29 |
| UY36445A (en) | 2016-07-29 |
| KR20170095955A (en) | 2017-08-23 |
| CN108064223B (en) | 2021-06-01 |
| TW201638073A (en) | 2016-11-01 |
| EA201791017A1 (en) | 2018-01-31 |
| EP3233850B1 (en) | 2019-04-03 |
| PL3233850T3 (en) | 2019-09-30 |
| ES2730757T3 (en) | 2019-11-12 |
| SI3233850T1 (en) | 2019-06-28 |
| EP3233850A1 (en) | 2017-10-25 |
| US9751874B2 (en) | 2017-09-05 |
| CA2971240A1 (en) | 2016-06-23 |
| BR102015031718A2 (en) | 2016-07-05 |
| JP2018500304A (en) | 2018-01-11 |
| CN108064223A (en) | 2018-05-22 |
| NZ732246A (en) | 2018-11-30 |
| AU2015365944A1 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251552A1 (en) | Hydroxy containing fxr (nr1h4) modulating compounds | |
| HK1245786B (en) | Novel fxr (nr1h4) modulating compounds | |
| IL263495A (en) | Fxr (nr1h4) modulating compounds | |
| IL263493B (en) | Fxr (nr1h4) modulating compounds | |
| GB201409044D0 (en) | New compounds | |
| HRP20181530T1 (en) | New sulfonylaminobenzamide compounds | |
| GB201404498D0 (en) | New compounds | |
| GB201416444D0 (en) | New compounds | |
| GB201403437D0 (en) | Easy click box | |
| HK1226059A1 (en) | Novel fxr (nr1h4) modulating compounds | |
| IL247610A0 (en) | Chemical compounds | |
| GB201418676D0 (en) | Compounds for use | |
| GB201409792D0 (en) | Compounds for use | |
| GB201401792D0 (en) | Beta-lactam compounds | |
| GB201421211D0 (en) | Chemical compounds | |
| GB201417346D0 (en) | New compounds | |
| GB201417344D0 (en) | New compounds | |
| GB201416430D0 (en) | New compounds | |
| GB201403122D0 (en) | New chemical compounds | |
| GB201402647D0 (en) | New compounds |